Global Interventional Oncology Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Get Exclusive Sample PDF of this Report Here

Global Interventional Oncology Market Analysis

The global interventional oncology market is projected to grow significantly, driven by the rising prevalence of cancer and the increasing adoption of minimally invasive procedures. The market benefits from advancements in imaging technologies, such as ultrasound, CT scans, and MRI, which enable precise targeting of tumors. Interventional oncology involves techniques such as thermal ablation, transarterial chemoembolization (TACE), and selective internal radiation therapy (SIRT) to treat cancer while minimizing damage to healthy tissues. Despite challenges such as high procedural costs, a shortage of skilled professionals, and stringent regulatory approvals, the market is expected to expand. North America is poised to dominate due to its advanced healthcare infrastructure and high adoption rate of these procedures. As awareness of the benefits of interventional oncology grows, the market is likely to see further expansion, promising improved patient outcomes and reduced recovery times compared to traditional cancer treatments. Overall, the market's growth is driven by the increasing need for effective and less invasive cancer treatments, which offer hope for better management and quality of life for patients worldwide.

Global Interventional Oncology Market Size

The global interventional oncology market size was valued at USD 2.63 billion in 2024 and is projected to reach USD 4.48 billion by 2032, with a CAGR of 6.89% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Global Interventional Oncology Market Trends

“Adoption of Minimally Invasive Procedures”

The adoption of minimally invasive procedures in interventional oncology has transformed cancer treatment by providing precise tumor targeting while minimizing damage to healthy tissues. Techniques such as thermal ablation, transarterial chemoembolization (TACE), and selective internal radiation therapy (SIRT) offer effective treatment options guided by advanced imaging technologies such as ultrasound, CT scans, and MRI. These procedures reduce recovery times, complications, and costs compared to traditional surgeries, making them increasingly popular among healthcare providers and patients. The growing trend towards these methods is driven by their convenience and improved patient outcomes. In addition, the rising prevalence of cancer, advancements in imaging technologies, and an aging population contribute to the expanding adoption of minimally invasive procedures in interventional oncology. As awareness of their benefits continues to grow, these techniques are expected to play a crucial role in enhancing cancer care worldwide, offering hope for better management and quality of life for patients. The market's future looks promising as technological innovations and increased acceptance further drive the trend towards minimally invasive treatments in interventional oncology.

Report Scope and Interventional Oncology Market Segmentation     

Get Exclusive Sample PDF of this Report Here

Global Interventional Oncology Market Definition

Interventional oncology (IO) is a specialized field within interventional radiology that focuses on the minimally invasive treatment of cancer and cancer-related conditions, guided by advanced medical imaging techniques such as X-ray, ultrasound, CT, and MRI. IO provides both diagnostic and therapeutic procedures, aiming to improve patient outcomes with reduced recovery times, minimal pain, and lower complication rates compared to traditional surgery. Diagnostic procedures, such as fine-needle aspiration and core needle biopsy, help in the accurate diagnosis of cancer.

Global Interventional Oncology Market Dynamics

Drivers

• Rising Global Cancer Incidence      

The rising global incidence of cancer is a key driver for the interventional oncology market. With the number of cancer cases increasing worldwide, there is an urgent need for effective and minimally invasive treatments. Interventional oncology offers solutions such as ablation and embolization procedures, which provide targeted and efficient cancer therapy with fewer complications and faster recovery times compared to traditional surgery. Factors such as aging populations, lifestyle changes, and environmental influences contribute to the growing cancer prevalence, further fueling the demand for interventional oncology. Advances in medical imaging and technology have improved the precision and effectiveness of these treatments, making them more appealing to patients and healthcare providers alike. In addition, increased awareness and early diagnosis of cancer are boosting the adoption of interventional oncology procedures. As a result, the market is experiencing significant growth and is poised to continue expanding in the coming years.

• Increasing Patient Awareness  

Patients are increasingly recognizing the advantages of minimally invasive oncology treatments, resulting in higher adoption rates. These treatments, which include options like laparoscopic surgeries, robotic-assisted procedures, and targeted therapies, offer numerous benefits over traditional open surgeries. Patients are particularly drawn to the reduced recovery times, decreased pain, and lower risk of complications associated with these minimally invasive procedures. Additionally, the advancements in medical technology and the proliferation of information through digital platforms have empowered patients to make more informed decisions about their healthcare options. Healthcare providers and institutions are also playing a crucial role in raising awareness by actively educating patients about the effectiveness and safety of these treatments. As a result, more patients are opting for minimally invasive oncology treatments, which not only improve their quality of life but also contribute to better overall treatment outcomes. The growing awareness and acceptance of these innovative medical interventions underscore the importance of continued education and outreach efforts in the field of oncology.

Opportunities

• Rapid Growth in the Interventional Oncology Market          

The Asia Pacific region is experiencing rapid growth in the interventional oncology market, driven by the rising prevalence of cancer and an increasing geriatric population. Factors such as aging populations, lifestyle changes, and environmental influences contribute to the growing cancer burden in the region. This surge in cancer cases creates a significant demand for advanced treatment options, making interventional oncology procedures more appealing. In addition, technological advancements and the adoption of minimally invasive techniques are further encouraging market growth. The Asia Pacific market is expected to see substantial expansion, presenting significant opportunities for healthcare providers and medical device manufacturers. As awareness of the benefits of interventional oncology increases, the region is poised to become a key player in the global market.

• Outpatient Preference Boosts Oncology

The preference for cost-effective and convenient outpatient or day-care procedures is expected to drive significant growth in the interventional oncology market. These procedures offer numerous advantages, including reduced healthcare costs, shorter hospital stays, and quicker recovery times, making them highly attractive to patients and healthcare providers alike. With advancements in medical technology and imaging, it has become possible to perform complex procedures on an outpatient basis, thus enhancing their appeal. Outpatient and day-care treatments not only improve patient experience but also optimize healthcare delivery by reducing the burden on hospitals and medical staff. As healthcare systems worldwide strive for efficiency and patient-centric care, the demand for minimally invasive, cost-effective treatments continues to rise. In addition, the growing awareness of these benefits among patients and the increasing emphasis on early cancer diagnosis contribute to the market's expansion. The trend toward outpatient and day-care procedures is anticipated to sustain, driving the growth of the interventional oncology market as it adapts to meet the evolving needs of patients and healthcare providers.

Restraints/Challenges

• High Procedural Costs of Interventional Oncology

The high cost of interventional oncology procedures is a significant barrier, particularly for patients in low-income regions. These advanced treatments often require specialized equipment, cutting-edge technology, and highly skilled professionals, all of which contribute to the overall expense. As a result, many patients cannot afford these procedures, limiting their access to potentially life-saving treatments. Furthermore, healthcare systems in low-income areas may struggle to invest in the necessary infrastructure and training required to offer interventional oncology services. This financial barrier highlights the need for cost-effective solutions and increased investment in healthcare to ensure equitable access to advanced cancer treatments globally.

• Shortage of Skilled Professionals

The limited availability of trained interventional oncologists and radiologists is a significant challenge for the widespread adoption and implementation of advanced interventional oncology procedures. These specialized treatments require highly skilled professionals who can effectively utilize advanced imaging technologies and perform intricate minimally invasive procedures. However, the current shortage of adequately trained personnel means that many healthcare facilities are unable to offer these treatments, especially in underdeveloped regions. This scarcity of skilled professionals can lead to delays in diagnosis and treatment, ultimately affecting patient outcomes.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Interventional Oncology Market Scope

The market is segmented on the basis by product , procedure, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Embolization Devices
• Ablation Devices
• Support Devices

Procedure

• Thermal Tumor Ablation
• Non-Thermal Tumor Ablation
• Transcatheter Arterial Chemoembolization
• Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
• Transcatheter Arterial Embolization/Bland Embolization

Application

• Liver Cancer
• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Kidney Cancer
• Bone Metastasis
• Others

End User

• Hospital
• Ambulatory Care Centers
• Research and Academia

Global Interventional Oncology Market Analysis

The market is analysed and market size insights and trends are provided by country, by traditional solution, by emerging solution and by deployment type as referenced above.

The countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, U.A.E, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America region is expected to dominate the market. The presence of prominent medical device manufacturers and well-established healthcare facilities drives the rapid adoption of interventional oncology procedures in the region. The United States, in particular, stands out as the largest market within North America, fueled by substantial investments in research and development, favorable reimbursement policies, and a high rate of adoption of advanced medical technologies. In addition, increased awareness among patients and healthcare providers about the benefits of minimally invasive procedures has further boosted demand for interventional oncology treatments. Canada also contributes significantly to the region's dominance, benefiting from government initiatives aimed at improving healthcare access and quality. Overall, North America's robust economic environment, technological advancements, and patient-centric care approach continue to propel the growth of the interventional oncology market in this region.

Asia Pacific region is fastest-growing region in market. This rapid growth is driven by the high burden of cancer and an aging population in the region. According to GLOBOCAN 2020, Asia accounted for nearly half of all cancer cases worldwide, with approximately 9.5 million new cancer cases and 5.8 million cancer deaths. The region is witnessing significant improvements in healthcare infrastructure, which, combined with rising awareness about the benefits of minimally invasive oncology treatments, is boosting market growth. Countries such as China, India, and Japan are at the forefront of this expansion due to their large populations, increasing healthcare expenditures, and ongoing advancements in medical technology. In addition, government initiatives and supportive policies aimed at enhancing cancer care and early diagnosis are further propelling the market. The Asia-Pacific region's dynamic economic environment, coupled with the increasing availability of advanced interventional oncology procedures, positions it as a key growth driver in the global market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Global Interventional Oncology Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Global Interventional Oncology Operating in the Market Are:

• HealthTronics, Inc. (U.S.)
• Trod Medical (U.S.)
• Sanarus (U.S.)
• Teleflex Incorporated (U.S.)
• IMBIOTECHNOLOGIES LTD. (United Kingdom)
• MedWaves, Inc. (U.S.)
• IceCure Medical Ltd (Israel)
• Terumo Europe NV (Belgium)
• Medtronic (U.S.)
• Boston Scientific Corporation (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Merit Medical Systems (U.S.)
• AngioDynamics (U.S.)
• Cook Medical (U.S.)
• BD (Becton, Dickinson and Company) (U.S.)
• Profound Medical (Canada)
• EDAP TMS (France)
• Sirtex SIR-Spheres Pty Ltd. (Australia)
• Accuray Incorporated (U.S.)
• Siemens Healthcare GmbH (Germany)

Latest Developments in Global Interventional Oncology Market 

• In December 2024, AngioDynamics Inc. achieved a significant milestone by receiving FDA clearance for their NanoKnife System for prostate tissue ablation. This clearance followed the completion of the pivotal PRESERVE clinical study, which evaluated the safety and effectiveness of the system for ablating prostate tissue in patients with intermediate-risk prostate cancer. The study demonstrated strong quality of life outcomes, with a high percentage of men remaining free from in-field, clinically significant disease at 12 months post-procedure. This development is expected to accelerate the adoption of the NanoKnife System and redefine the standard of care for prostate health
• In November 2024, Boston Scientific announced that it had entered into a definitive agreement to acquire Intera Oncology Inc., a privately held medical device company. Intera Oncology provides the Intera 3000 Hepatic Artery Infusion Pump and floxuridine, a chemotherapy drug, both of which are approved by the U.S. Food and Drug Administration. The Intera 3000 pump is used to administer hepatic artery infusion (HAI) therapy to treat tumors in the liver, primarily caused by metastatic colorectal cancer
• In September 2024, Varian, a Siemens Healthineers company, announced a 10-year agreement with Ballad Health to bring advanced oncology treatment services to patients in rural communities across the Appalachian Highlands in Northeast Tennessee, Southwest Virginia, northwestern North Carolina, and southeastern Kentucky. This transformational oncology collaboration aims to deliver advanced treatment technology through a highly integrated digital network, accelerating the patient journey from screening to survivorship. The agreement includes a portfolio of products and services supporting a unified oncology ecosystem, such as Varian’s ARIA CORE oncology management solution and the Varian Executive Partnership program
• In November 2023, ProSense received regulatory approval in India from the Central Drugs Standard Control Organisation (CDSCO) based on updated regulatory requirements. This approval allows ProSense to be marketed and sold in India, enhancing its presence in the market. The ProSense system, developed by IceCure Medical, is a minimally invasive cryoablation technology that destroys tumors by freezing, offering an alternative to surgical tumor removal. This approval is expected to drive the adoption of ProSense in India, particularly for breast cancer cryoablation procedures
• In May 2023, Varian, a Siemens Healthineers company, introduced the Isolis™ cryoprobe, a single-use, disposable device designed for use with CryoCare® systems to improve procedural efficiency and precision for cryoablation. The Isolis cryoprobe offers interventional radiologists greater control, precision, and efficiency during cryoablation procedures. It features a small 2.1mm/14-gauge shaft and a sharp probe tip for smooth and accurate placement. In addition, it is the first cryoprobe to offer optional integration with the Siemens Healthineers myNeedle Laser guidance system, enhancing predictability and precision during image-guided interventional procedures

SKU-59862